Forte Biosciences, Inc.
FBRX2026/8/27 下市- 產業
- Pharmaceutical Preparations
- SEC CIK
- 0001419041
Forte Biosciences, Inc. 已在 2026/8/27 下市；內部人最後一份 Form 4 在 2026/8/27 申報；2026 年第 2 季末有 86 家機構在 13F 申報持有，市值合計 $4.33 億；沒有大師持有。
持有 FBRX 5% 以上的大股東
最新一份 Schedule 13D 或 13G 申報持有 Forte Biosciences, Inc. 5% 以上的持有人，依持股比例由大到小；變化是跟這位持有人的上一份申報比。
| 持有人 | 最新表單 | 持股 | 變化 | 首次申報 | 最新申報 | 原文 |
|---|---|---|---|---|---|---|
| Tybourne Capital Management (HK) Ltd | 13G/A | 9.99%股數 126.8 萬 | 0.00 個百分點原本 9.99% | 2024/2/143 份 | 2025/8/4 | SEC |
| Janus Henderson Group PLC | 13G/A | 9.30%股數 189.4 萬 | +6.80 個百分點原本 2.50% | 2025/2/147 份 | 2026/8/13 | SEC |
| MPM Oncology Impact Management LP | 13G | 7.20%股數 100.1 萬 | 新申報 | 2026/5/151 份 | 2026/5/15 | SEC |
| OrbiMed Advisors LLC | 13G/A | 6.20%股數 126.5 萬 | +1.90 個百分點原本 4.30% | 2021/2/125 份 | 2026/8/14 | SEC |
| BlackRock, Inc. | 13G | 5.90%股數 120.5 萬 | 新申報 | 2026/7/281 份 | 2026/7/28 | SEC |
| Affinity Asset Advisors, LLC | 13G/A | 5.60%股數 114.5 萬 | −1.70 個百分點原本 7.30% | 2025/12/234 份 | 2026/8/13 | SEC |
持股是每位持有人最新一份申報的數字。最後一份是舊格式（2024 年 12 月 18 日以前）的持有人沒有持股比例紀錄，不列在這裡；公司被收購或下市之後，持有人通常就不再申報。
13D 與 13G 申報
Forte Biosciences, Inc. 的 105 份 Schedule 13D、13G 申報，由新到舊，包括沒有持股比例的舊格式申報。
| 申報時間（美東） | 申報人 | 表單 | 持股 | 變化 | 事件日 | 原文 |
|---|---|---|---|---|---|---|
| 2024/2/14 | Perceptive Advisors LLC | 13G/A舊制 | – | – | – | SEC |
| 2024/2/14 | Alger Associates Inc | 13G/A舊制 | – | – | – | SEC |
| 2024/2/14 | Tybourne Capital Management (HK) Ltd | 13G舊制 | – | 新申報 | – | SEC |
| 2024/2/14 | Farallon Capital Partners, L.P. | 13G/A舊制 | – | – | – | SEC |
| 2024/1/11 | BML Investment Partners, L.P. | 13D/A舊制 | – | – | – | SEC |
| 2024/1/9 | Funicular Funds, LP | 13D/A舊制 | – | – | – | SEC |
| 2024/1/5 | Camac Fund, LP | 13D/A舊制 | – | – | – | SEC |
| 2023/9/15 | BML Investment Partners, L.P. | 13D/A舊制 | – | – | – | SEC |
| 2023/9/12 | Alger Associates Inc | 13G舊制 | – | 新申報 | – | SEC |
| 2023/9/8 | Perceptive Advisors LLC | 13G舊制 | – | – | – | SEC |
| 2023/8/23 | Camac Fund, LP | 13D舊制 | – | – | – | SEC |
| 2023/8/15 | Wagner Paul A. | 13D/A舊制 | – | – | – | SEC |
| 2023/8/10 | ATG Fund II LLC | 13D/A舊制 | – | – | – | SEC |
| 2023/8/10 | Biotechnology Value Fund L P | 13G舊制 | – | – | – | SEC |
| 2023/8/10 | Farallon Capital Partners, L.P. | 13G舊制 | – | 新申報 | – | SEC |
| 2023/8/3 | Camac Fund, LP | 13D/A舊制 | – | – | – | SEC |
| 2023/7/6 | Funicular Funds, LP | 13D/A舊制 | – | – | – | SEC |
| 2023/7/5 | Camac Fund, LP | 13D/A舊制 | – | – | – | SEC |
| 2023/5/25 | Camac Fund, LP | 13D/A舊制 | – | – | – | SEC |
| 2023/4/10 | JEC II Associates, LLC | 13G舊制 | – | 新申報 | – | SEC |
| 2023/3/29 | BML Investment Partners, L.P. | 13D/A舊制 | – | – | – | SEC |
| 2023/2/21 | Camac Fund, LP | 13D/A舊制 | – | – | – | SEC |
| 2022/9/28 | Camac Fund, LP | 13D/A舊制 | – | – | – | SEC |
| 2022/9/22 | Funicular Funds, LP | 13D/A舊制 | – | – | – | SEC |
| 2022/9/12 | Morgan Stanley | 13G/A舊制 | – | – | – | SEC |
| 2022/8/24 | Funicular Funds, LP | 13D/A舊制 | – | – | – | SEC |
| 2022/8/18 | Camac Fund, LP | 13D/A舊制 | – | – | – | SEC |
| 2022/8/16 | BML Investment Partners, L.P. | 13D/A舊制 | – | – | – | SEC |
| 2022/8/9 | Camac Fund, LP | 13D/A舊制 | – | – | – | SEC |
| 2022/8/4 | ATG Fund II LLC | 13D舊制 | – | 新申報 | – | SEC |
| 2022/8/1 | Camac Fund, LP | 13D舊制 | – | 新申報 | – | SEC |
| 2022/7/19 | Funicular Funds, LP | 13D/A舊制 | – | – | – | SEC |
| 2022/7/816:56 ET | BlackRock Inc. | 13G舊制 | – | – | – | SEC |
| 2022/7/7 | BML Investment Partners, L.P. | 13D/A舊制 | – | – | – | SEC |
| 2022/7/5 | Funicular Fund, LP | 13D舊制 | – | 新申報 | – | SEC |
| 2022/5/24 | BML Investment Partners, L.P. | 13D舊制 | – | – | – | SEC |
| 2022/5/4 | BML Investment Partners, L.P. | 13G舊制 | – | 新申報 | – | SEC |
| 2022/2/14 | Perceptive Advisors LLC | 13G/A舊制 | – | – | – | SEC |
| 2022/2/14 | Biotechnology Value Fund L P | 13G/A舊制 | – | – | – | SEC |
| 2022/2/14 | Point72 Asset Management, L.P. | 13G/A舊制 | – | – | – | SEC |
| 2022/2/11 | OrbiMed Advisors LLC | 13G/A舊制 | – | – | – | SEC |
| 2022/2/11 | Morgan Stanley | 13G舊制 | – | 新申報 | – | SEC |
| 2022/2/416:12 ET | BlackRock Inc. | 13G舊制 | – | 新申報 | – | SEC |
| 2022/2/3 | Franklin Resources Inc | 13G/A舊制 | – | – | – | SEC |
| 2021/10/13 | ArrowMark Colorado Holdings LLC | 13G/A舊制 | – | – | – | SEC |
| 2021/9/21 | Oliveira Steven Michael | 13G/A舊制 | – | – | – | SEC |
| 2021/9/16 | Wagner Paul A. | 13D/A舊制 | – | – | – | SEC |
| 2021/9/13 | Logos Global Management LP | 13G舊制 | – | 新申報 | – | SEC |
| 2021/5/18 | Point72 Asset Management, L.P. | 13G舊制 | – | 新申報 | – | SEC |
| 2021/4/12 | ArrowMark Colorado Holdings LLC | 13G/A舊制 | – | – | – | SEC |
Form 144：內部人預計賣出
高階主管、董事與其他關係人預計賣出 Forte Biosciences, Inc. 股票的通知。
還沒有 Forte Biosciences, Inc. 的 Form 144 申報。